Further, the Board of Directors of the Company at its adjourned meeting held on 29 March 2022, on recommendation of the Audit Committee has also considered and approved the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals ('Transferor Company') with Alembic Pharmaceuticals ('Transferee Company') and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 and rules framed thereunder ('Scheme').

The Appointed date for the Scheme would be 1 April 2021.